Anti Cd 20 Ocrevus denied as not FDA-approved for this use by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for anti cd20 ocrevus are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS May Issue a "Not FDA-Approved" Denial for Ocrelizumab

Ocrelizumab (Ocrevus) holds FDA approval for both relapsing forms of multiple sclerosis and primary progressive multiple sclerosis — making a blanket "not FDA-approved" denial factually incorrect for those indications. When BCBS issues this type of denial, it usually means one of three things: the claim was coded to an indication the plan does not recognize as covered, the specific MS subtype documented in the chart does not match what the insurer's system expects, or the denial was generated in error. In all three cases, the denial is contestable.

## Why This Denial Is Appealable

An incorrect FDA-approval denial is among the most straightforward to overturn because the FDA approval status of ocrelizumab for MS is publicly verifiable in the prescribing label. Under ACA §2719 and ERISA §503, you have the right to an internal appeal and, if upheld, an independent external review. The external-review window is typically around four months from the adverse determination; confirm the deadline in your plan documents. Expedited review is available when delay poses a serious health risk.

## Your Appeal Timeline

1. Request the denial letter and the specific reason code — ask BCBS to identify the exact basis: which indication, which code, or which policy provision triggered the denial. 2. File the internal appeal immediately, attaching the FDA approval documentation. 3. If the denial was a coding error, work with the prescriber's office to correct the diagnosis or procedure code and resubmit alongside the appeal. 4. Escalate to external review if the internal appeal is denied.

## Documentation to Gather

• FDA prescribing label for ocrelizumab: the current label is publicly available from the FDA and explicitly lists the approved indications. Include a copy with your appeal.
• Diagnosis confirmation: neurology notes, MRI reports, and any subspecialty records that clearly establish the patient's MS diagnosis and subtype as an FDA-approved indication for ocrelizumab.
• Correct coding documentation: confirm with the prescriber's billing office that the ICD-10 diagnosis code and the drug's HCPCS/J-code are correctly matched to the approved indication.
• Prescriber cover letter: a brief letter from the neurologist confirming that the prescribed use falls squarely within the FDA-approved labeling, referencing the label by name.
• Plan's own coverage policy: obtain BCBS's published policy for ocrelizumab and show that the patient's indication is covered under that policy.

## Criteria-Mapping Structure

Use a side-by-side table to make the appeal undeniable:

| Denial Basis | Correct Information | Supporting Document | |---|---|---| | "Not FDA-approved" | FDA approval confirmed for [patient's MS type] | FDA label (attached) | | Diagnosis code mismatch (if applicable) | Corrected ICD-10 code | Prescriber billing note | | Indication alignment | Patient's documented diagnosis matches label | Neurology notes, [Date] |

Because FDA approval status is a matter of public record, an external IRO reviewing this denial has strong grounds to overturn it if the documentation clearly shows the prescribed use is on-label.